If you are a Healthcare Professional and you would like to log in to access this content, please click "Login".
You are now leaving the Lilly Medical Web site
Please use a minimum of three unique search wordsOur search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Taltz ® (ixekizumab)
This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information:
Taltz Summary of Product Characteristics (SmPC)
Taltz® (ixekizumab): What is the recommendation, when a dose is missed by patients with axial spondyloarthritis?
The Taltz Summary of Product Characteristics does not contain any specific recommendation on how to proceed when a dose is missed. Please refer to the additional information provided in the response below.
US Taltz package insert states that if a dose is missed, administer
the dose as soon as possible. Thereafter, resume dosing at the
regular scheduled time.1
the ixekizumab clinical development program, ixekizumab was
administered at approximately the same time each day, as much as
the pivotal COAST-V AS/r-axSpA clinical trial, injections not
administered on the scheduled day were to be administered
3 days of the scheduled day from week 0 to week 16, and
5 days of the scheduled day after week 16.3
the pivotal COAST-W AS/r-axSpA clinical trial, the missed injection
was to be administered as soon as possible but not within 5 days of
the next scheduled dose. Injections were to be at least 5 days apart
and subsequent study visits were not to be modified according to this
the pivotal COAST-X nr-axSpA clinical trial, the missed
injection was to be administered as soon as possible but not within 5
days of the next scheduled dose. Injections were to be at least 5
days apart and subsequent study visits were not to be modified
according to this delay.3
Taltz [package insert]. Indianapolis, IN: Eli Lilly and Company;